Saxenda vs Generic Liraglutide: Daily GLP-1 Brand vs Generic Compared

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Liraglutide is the original commercially successful GLP-1 receptor agonist for chronic indications. Novo Nordisk obtained FDA approval for the molecule as Victoza in January 2010 for type 2 diabetes, and again as Saxenda in December 2014 for chronic weight management. The two products contain the same molecule at different labelled doses: Victoza maintenance dose is 1.8 mg daily, Saxenda maintenance dose is 3.0 mg daily.

Both products are subcutaneous injection pens. The molecule’s defining pharmacokinetic feature is its 13-hour terminal half-life — long enough to support once-daily dosing, but much shorter than the once-weekly semaglutide (~7 days) or tirzepatide (~5 days). This is the principal reason liraglutide has been increasingly displaced as first-choice GLP-1 since 2017: the weekly injection is meaningfully easier to adhere to than a daily one, and the newer molecules produce stronger weight-loss outcomes.

Lilly’s US composition patent on liraglutide expired in June 2024, and FDA-approved generic liraglutide injection entered US retail pharmacies later that year. The patent-expiry-driven price drop arrived just as the broader GLP-1 prescribing landscape was shifting heavily to semaglutide and tirzepatide.

TL;DR comparison table

How liraglutide compares to semaglutide and tirzepatide

Within the GLP-1 receptor agonist class, the three commercially significant molecules differ on three dimensions:

• Dosing frequency: liraglutide daily; semaglutide weekly; tirzepatide weekly.
• Weight-loss magnitude (placebo-subtracted at maximum dose): liraglutide ~8% (Saxenda 3.0 mg); semaglutide ~15% (Wegovy 2.4 mg, STEP 1); tirzepatide ~22.5% (Zepbound 15 mg, SURMOUNT-1).
• HbA1c reduction (T2DM, maximum dose): liraglutide ~1.5 percentage points (Victoza 1.8 mg); semaglutide ~1.4–1.6 (Ozempic 1.0 mg) or ~2.0 (Ozempic 2.0 mg); tirzepatide ~2.0–2.4 (Mounjaro 15 mg).

The clinical pattern: liraglutide is meaningfully less effective than the once-weekly molecules for both weight loss and glycaemic control, and requires more frequent injections. Its remaining clinical roles in 2026 are mostly in patients with specific contraindications to the longer-acting molecules, or in clinical settings where the daily-dosing pharmacokinetics are advantageous.

For the three-molecule mechanism comparison including the investigational triple-agonist retatrutide, see Retatrutide vs Tirzepatide vs Semaglutide.

The SCALE trial: liraglutide for weight management

The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trial program established Saxenda’s FDA approval. The pivotal SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM, 2015¹) randomised 3,731 adults with BMI ≥30 (or ≥27 with comorbidity) to liraglutide 3.0 mg daily or placebo, plus lifestyle intervention, for 56 weeks. Mean weight loss: 8.0% on liraglutide vs 2.6% on placebo. 63% of the liraglutide group lost ≥5% of body weight; 33% lost ≥10%.

The 8% mean weight loss is meaningful but is substantially less than what semaglutide 2.4 mg achieves (~15% in STEP 1) or tirzepatide 15 mg (~22.5% in SURMOUNT-1). For most patients, the once-weekly molecules with stronger weight-loss outcomes are now the first-line choice.

Mechanism and bioequivalence

Liraglutide is a 31-amino-acid GLP-1 analogue with a C16 fatty acid side chain at lysine-26 (the modification that enables albumin binding and extends half-life from native GLP-1’s 1–2 minutes to liraglutide’s 13 hours). Mechanism: GLP-1 receptor agonism producing glucose-dependent insulin release, glucagon suppression at elevated glucose, slowed gastric emptying, and central appetite suppression — the standard GLP-1 mechanism set.

Generic liraglutide products approved by the FDA since 2024 are Orange Book-rated equivalent to branded Saxenda/Victoza and substitutable at the pharmacy counter. The molecule and pharmacology are identical across brand and generic.

Price comparison

Even at the generic liraglutide price point, the cost-per-percent-weight-loss is unfavourable compared with branded once-weekly semaglutide or tirzepatide via insurance or co-pay-assistance programs. The economic case for liraglutide in 2026 is principally for users without insurance coverage for the once-weekly options.

Side effects: identical molecule, identical profile

Liraglutide’s side-effect profile is intrinsic to the molecule and applies across brand and generic:¹

• Nausea (~30–40% during initiation, decreasing with adaptation)
• Vomiting (~15–20% during initiation)
• Diarrhoea (~17%)
• Constipation (~19%)
• Abdominal pain (~15%)
• Headache (~14%)
• Injection-site reactions (~12%) — more common with daily injection than weekly
• Hypoglycaemia (significant when combined with insulin or sulfonylureas; rare as monotherapy)

GI side-effect rates during initiation are similar to or slightly higher than semaglutide. The daily injection produces more cumulative injection-site reactions over time than weekly dosing.

Contraindications

Who should choose liraglutide in 2026?

Given that semaglutide and tirzepatide produce substantially better weight-loss outcomes with weekly dosing, liraglutide’s specific clinical niches in 2026 are:

• Patients without insurance access to semaglutide or tirzepatide — generic liraglutide at $300–$500/month is the cheapest FDA-approved GLP-1 in the US market.
• Patients who don’t tolerate weekly dosing — some patients prefer daily dosing for either GI tolerability (the dose distributes more evenly) or psychological reasons (the daily routine reinforces adherence).
• Patients with specific drug-interaction concerns — liraglutide’s shorter half-life produces faster recovery to baseline if a discontinuation becomes necessary (e.g., elective surgery, planned pregnancy).
• Patients already established on Victoza/Saxenda who are tolerating it well — switching molecules within the GLP-1 class is not necessarily indicated if current therapy is working.

For most patients starting GLP-1 therapy in 2026, the once-weekly options (semaglutide, tirzepatide) are stronger choices on both efficacy and convenience. See Wegovy vs Compounded Semaglutide and Mounjaro vs Generic Tirzepatide for those molecules.

What MedsBase stocks (and doesn’t stock)

MedsBase does not currently stock liraglutide research-grade peptide or finished-product. Our GLP-1 peptide catalogue includes semaglutide, tirzepatide, retatrutide, cagrilintide, mazdutide, and survodutide — the molecules with stronger weight-loss outcomes or specific mechanistic features. If you are specifically researching liraglutide, the FDA-approved generic supply chain (US retail since 2024) is the standard source. Browse our peptides catalogue for the molecules we do stock under research-grade labelling.

Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.

Frequently Asked Questions

Is generic liraglutide the same molecule as Saxenda?

Yes. Both contain liraglutide at the same labelled doses (0.6, 1.2, 1.8, 2.4, 3.0 mg). The mechanism, dosing, half-life, weight-loss effect, and side-effect profile are pharmacologically identical. The differences are the manufacturer, the inactive excipients, and the price.

Why is liraglutide less effective than semaglutide?

Liraglutide has a shorter half-life (13 hours vs 7 days), requiring daily rather than weekly dosing. The molecule binds the GLP-1 receptor with comparable affinity but produces lower steady-state plasma levels, and the daily peak-trough cycling produces less consistent GLP-1 signalling than the steady weekly semaglutide profile. The clinical consequence is approximately 7–15 percentage points less weight loss at maximum doses.

Should I switch from Saxenda to semaglutide?

For most patients who are tolerating but not maximally benefiting from Saxenda, switching to once-weekly semaglutide (Wegovy 2.4 mg) is a reasonable next step. The molecule is in the same class, the same boxed-warning contraindications apply, and the weight-loss outcomes are meaningfully stronger. Switching should be done in conversation with your prescriber with appropriate titration.

Why does MedsBase not stock liraglutide?

Liraglutide is being progressively replaced by semaglutide and tirzepatide as first-choice GLP-1 receptor agonists in the global market. MedsBase’s GLP-1 peptide catalogue prioritises the molecules with stronger weight-loss outcomes or specific mechanistic features (dual GLP-1+GIP agonism in tirzepatide, triple GLP-1+GIP+glucagon agonism in retatrutide). For researchers specifically working with liraglutide, the FDA-approved generic supply chain since 2024 is the standard source.

Are the side effects of generic liraglutide the same as Saxenda?

Yes. Both produce nausea (around 30 to 40 percent during initiation), vomiting (around 15 to 20 percent), diarrhoea, constipation, abdominal pain, headache, and injection-site reactions at similar rates. The molecule is identical and the pharmacology is identical between brand and generic.

What about Victoza?

Victoza is the same molecule as Saxenda (liraglutide) at a lower maintenance dose (1.8 mg daily vs 3.0 mg) and FDA-approved for type 2 diabetes rather than weight management. Generic liraglutide is interchangeable with both Saxenda and Victoza at the appropriate equivalent dose. Use depends on indication and prescriber-specified dose.

Is liraglutide compounded the way semaglutide was?

Liraglutide was not listed on the FDA drug shortage register, so the 503A/503B compounding pathway that operated for semaglutide and tirzepatide did not develop similarly for liraglutide. With generic liraglutide now available in US retail since 2024, the compounding case is also weaker. Some 503B outsourcing facilities continue to produce liraglutide under narrower indications.

Sources

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015;373(1):11–22.
2. US Food and Drug Administration. NDA 022341, Victoza (liraglutide). Approval letter, 25 January 2010.
3. US Food and Drug Administration. NDA 206321, Saxenda (liraglutide). Approval letter, 23 December 2014.
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine. 2016;375(4):311–322.

Last clinically reviewed: 18 May 2026.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.